Nanna Therapeutics is a small-molecule focused therapeutics biotech subsidiary of Astellas, a Japanese global pharmaceutical company. Nanna and Mitobridge together comprise of the Mitobridge Division, a US- and UK-based research engine of Astellas reporting in to the Astellas Chief Scientific Officer, together we work as part of the Astellas Primary Focus Mitochondria area of research. Mitobridge is a Boston-based biotech acquired by Astellas in 2018, and Nanna Therapeutics, is a Cambridge, UK-based biotech, acquired in 2020. Further information can be found at www.nannatherapeutics.com.
View Top Employees from Nanna TherapeuticsWebsite | http://www.nannatherapeutics.com |
Revenue | $3 million |
Employees | 20 (20 on RocketReach) |
Founded | 2012 |
Phone | +44 1223 423506 |
Technologies |
JavaScript,
HTML,
PHP
+10 more
(view full list)
|
Industry | Biotechnology Research, Manufacturing General, Biotechnology, Microbiomes, Manufacturing, Science and Engineering, Natural Small Molecules, Health Care, Infectious Diseases, Medical, Natural Products, Therapeutics, Oncology, Mitochondrial Disease |
SIC | SIC Code 2834 Companies, SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 5417 Companies, NAICS Code 54171 Companies, NAICS Code 541711 Companies, NAICS Code 541 Companies, NAICS Code 54 Companies |
Looking for a particular Nanna Therapeutics employee's phone or email?
The Nanna Therapeutics annual revenue was $3 million in 2024.
Chris Doe is the Site Head of Nanna Therapeutics.
20 people are employed at Nanna Therapeutics.
The NAICS codes for Nanna Therapeutics are [5417, 54171, 541711, 541, 54].
The SIC codes for Nanna Therapeutics are [2834, 283, 28].